OTS964 (hydrochloride)
CAT:
804-HY-12467-01
Size:
10 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
OTS964 (hydrochloride)
- CAS Number: 1338545-07-5
- UNSPSC Description: OTS964 hydrochloride is an orally active, high affinity and selective TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor with an IC50 of 28 nM[1]. OTS964 hydrochloride is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a Kd of 40 nM[2].
- Target Antigen: Apoptosis; CDK; TOPK
- Type: Reference compound
- Related Pathways: Apoptosis;Cell Cycle/DNA Damage
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/OTS-964.html
- Purity: 99.74
- Solubility: DMSO : ≥ 83.33 mg/mL|H2O : 2 mg/mL (ultrasonic;warming;heat to 60°C)
- Smiles: OC1=CC(C)=C2C(C3=C(SC=C3)C(N2)=O)=C1C4=CC=C([C@@H](C)CN(C)C)C=C4.Cl
- Molecular Weight: 428.97
- References & Citations: [1]Matsuo Y, et al. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition ofcytokinesis. Sci Transl Med. 2014 Oct 22;6(259):259ra145.|[2]Lin A, et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med. 2019 Sep 11;11(509).|[3]Lu H, et al. TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ. Cell Death Dis. 2019 Aug 5;10(8):583.Cell Death Dis. 2019 Aug 5;10(8):583. |Cell. 2021 Jun 10;184(12):3143-3162.e32.|Nature. 2022 Sep;609(7928):829-834.|SSRN. 2022 Nov 21.|Adv Sci (Weinh). 2024 Feb 2:e2308496.|iScience. 2023 Jun 16.|J Eur Acad Dermatol Venereol. 2023 Dec 22.
- Shipping Conditions: Room Temperature
- Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
- Clinical Information: No Development Reported